19 results on '"Lopa SH"'
Search Results
2. Novel Approach to Identify Severe Maternal Morbidity Clusters: A Latent Class Analysis.
- Author
-
Ibarra AJ, Lopa SH, Phan BN, Himes K, Butters MA, Beck S, and Catov JM
- Abstract
Objective: Whether clusters exist within severe maternal morbidity (SMM), a set of life-threatening heterogeneous conditions, is not known. Our primary objective was to identify SMM clusters using a data-driven clustering technique, their associated predictors and outcomes., Study Design: From 2008 to 2017, we used a delivery database supplemented by state data and medical record abstraction from a single institution in Pennsylvania. To identify SMM clusters, we applied latent class modeling that included 23 conditions defined by 21 Centers for Disease Control SMM indicators, intensive care unit (ICU) admission, or prolonged postpartum length of stay. Logistic regression models estimated risk for SMM clusters and associations between clusters and maternal and neonatal outcomes., Results: Among 97,492 deliveries, 2.7% ( N = 2,666) experienced SMM by any of the 23 conditions. Four clusters were identified as archetypes of SMM. Deliveries labeled as Hemorrhage (37.7%, N = 1,004) were characterized by blood transfusions and sickle cell anemia; Critical Care (28.1%, N = 748) by ICU admission and amniotic embolism; Vascular (24.5%, N = 654) by cerebrovascular conditions; and Shock (9.8%, N = 260) by ventilatory support and shock. Hypertensive disorders of pregnancy, depression, and Medicaid insurance were associated with Shock cluster. People in all clusters had a high risk of maternal death within 1 year (odds ratio: 12.0, 95% confidence interval: 6.2-23). Infants born to those in the shock cluster had the highest odds of neonatal death, low Apgar scores, and neonatal ICU admission., Conclusion: We identified four novel SMM clusters that may help understand the collection of conditions defining SMM, underlying pathways and the importance of comorbidities such as depression and social determinants of health markers that amplify the well-established risk factors for SMM such as hypertensive disorders of pregnancy., Key Points: · A total of 2.7% of deliveries experienced SMM events.. · There are four distinct SMM clusters: Hemorrhage, Critical Care, Vascular, and Shock.. · Not all SMM clusters bear the same risk for adverse perinatal outcomes.., Competing Interests: None declared., (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)
- Published
- 2024
- Full Text
- View/download PDF
3. Inflammatory, metabolic, and endothelial biomarkers before and after pregnancy complications.
- Author
-
Sun B, Gunderson EP, Bertolet M, Lopa SH, Bryan SG, Lewis CE, and Catov JM
- Subjects
- Humans, Female, Pregnancy, Adult, Premature Birth epidemiology, Premature Birth blood, Young Adult, Inflammation blood, Hypertension, Pregnancy-Induced blood, Hypertension, Pregnancy-Induced epidemiology, Intercellular Adhesion Molecule-1 blood, Pregnancy Complications blood, Biomarkers blood, C-Reactive Protein analysis, Diabetes, Gestational blood, Leptin blood, Adiponectin blood
- Abstract
Women with gestational diabetes mellitus (GDM), hypertensive disorders of pregnancy (HDP), and preterm birth (PTB) have excess cardiovascular disease compared with those with uncomplicated births, perhaps related to prepregnancy inflammation, dysmetabolism, or endothelial dysfunction. We included 1238 women in the Coronary Artery Risk Development in Young Adults Study (1985-2011) with 2215 births classified according to outcomes (term, uncomplicated births were the referent). Using repeated measures analysis of variance, we estimated prepregnancy and postpregnancy biomarkers, as well as biomarker change according to pregnancy outcomes, adjusted for confounders. GDM and term HDP groups had higher prepregnancy high-sensitivity C-reactive protein (hsCRP) (+0.37 [95% CI, 0.08-0.65]; +0.29 [95% CI, 0.04-0.55] log mg/L), higher leptin (+0.29 [95% CI, 0.09-0.50]; +0.37 [95% CI, 0.17-0.56] log ng/ml), and lower adiponectin (-0.25 [95% CI, -0.36 to -0.13); -0.11 [95% CI, -0.22 to -0.01] log ng/ml) values than those with uncomplicated births, and these profiles persisted in magnitude postpregnancy. Controlling for body mass index attenuated most profiles, except that lower prepregnancy adiponectin remained associated with GDM. PTB without HDP or GDM was related to lower prepregnancy hsCRP and soluble intercellular adhesion molecule-1 (-0.31 [95% CI, -0.56 to -0.06] log mg/L; -0.05 [95% CI, -0.09 to -0.01] log ng/ml) and a larger leptin increase from before to after pregnancy (+0.20 [95% CI, 0.02-0.37] log ng/ml). Prepregnancy inflammation and metabolic dysfunction contributed to GDM and HDP, perhaps due to higher body mass index. PTB may be related to adverse metabolic changes postpregnancy, although the unexpected endothelial biomarker profile warrants further study., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
4. Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis.
- Author
-
Gibbons E, Taya M, Wu H, Lopa SH, Moss J, Henske EP, McCormack FX, and Hammes SR
- Subjects
- Humans, Animals, Female, Mice, Cell Line, Tumor, Mechanistic Target of Rapamycin Complex 1 metabolism, Tuberous Sclerosis Complex 2 Protein genetics, Tuberous Sclerosis Complex 2 Protein metabolism, Cell Proliferation, Lymphangioleiomyomatosis metabolism, Lymphangioleiomyomatosis pathology, Lymphangioleiomyomatosis genetics, Membrane Glycoproteins metabolism, Membrane Glycoproteins genetics, Biomarkers, Tumor metabolism
- Abstract
Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease affecting almost exclusively female-sexed individuals. The cysts represent regions of lung destruction caused by smooth muscle tumors containing mutations in one of the two tuberous sclerosis (TSC) genes. mTORC1 inhibition slows but does not stop LAM advancement. Furthermore, monitoring disease progression is hindered by insufficient biomarkers. Therefore, new treatment options and biomarkers are needed. LAM cells express melanocytic markers, including glycoprotein non-metastatic melanoma protein B (GPNMB). The function of GPNMB in LAM is currently unknown; however, GPNMB's unique cell surface expression on tumor versus benign cells makes GPNMB a potential therapeutic target, and persistent release of its extracellular ectodomain suggests potential as a serum biomarker. Here, we establish that GPNMB expression is dependent on mTORC1 signaling, and that GPNMB regulates TSC2-null tumor cell invasion in vitro. Further, we demonstrate that GPNMB enhances TSC2-null xenograft tumor growth in vivo, and that ectodomain release is required for this xenograft growth. We also show that GPNMB's ectodomain is released from the cell surface of TSC2-null cells by proteases ADAM10 and 17, and we identify the protease target sequence on GPNMB. Finally, we demonstrate that GPNMB's ectodomain is present at higher levels in LAM patient serum compared to healthy controls and that ectodomain levels decrease with mTORC1 inhibition, making it a potential LAM biomarker.
- Published
- 2024
- Full Text
- View/download PDF
5. Postnatal oogenesis leads to an exceptionally large ovarian reserve in naked mole-rats.
- Author
-
Brieño-Enríquez MA, Faykoo-Martinez M, Goben M, Grenier JK, McGrath A, Prado AM, Sinopoli J, Wagner K, Walsh PT, Lopa SH, Laird DJ, Cohen PE, Wilson MD, Holmes MM, and Place NJ
- Subjects
- Animals, Female, Cell Differentiation, Germ Cells, Mitosis, Ovary, Mole Rats, Oogenesis, Ovarian Reserve
- Abstract
In the long-lived naked mole-rat (NMR), the entire process of oogenesis occurs postnatally. Germ cell numbers increase significantly in NMRs between postnatal days 5 (P5) and P8, and germs cells positive for proliferation markers (Ki-67, pHH3) are present at least until P90. Using pluripotency markers (SOX2 and OCT4) and the primordial germ cell (PGC) marker BLIMP1, we show that PGCs persist up to P90 alongside germ cells in all stages of female differentiation and undergo mitosis both in vivo and in vitro. We identified VASA+ SOX2+ cells at 6 months and at 3-years in subordinate and reproductively activated females. Reproductive activation was associated with proliferation of VASA+ SOX2+ cells. Collectively, our results suggest that highly desynchronized germ cell development and the maintenance of a small population of PGCs that can expand upon reproductive activation are unique strategies that could help to maintain the NMR's ovarian reserve for its 30-year reproductive lifespan., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
6. Children That Are Victims to Civil War: A Social Approach through Art and Culture-Molega, a Traditional Poso Children's Game: Special Issue.
- Author
-
Abdul Latief J, Ibnu Khaldun R, and Hatta I
- Abstract
Molega is a traditional game that is very popular among children and teenagers and is widely played. Molega has many benefits; it fosters solidarity and social harmony, builds responsibility, and develops honesty, sportsmanship, and egalitarian attitudes and behaviors, which make children happier in terms of mental growth. Before the Poso communal conflict, some games could still be played, especially those that were played in groups. However, several conditions hinder teaching molega to the next generation, such as the increase in modern games that children find more interesting and "prestigious". In addition, some traditional game tools are difficult to find (such as wood shoots), and the amount of vacant land needed as a game medium continues to decrease. Prolonged conflict has also weakened the molega tradition, but it has had many positive impacts. The results of the social approach applied in this study found that molega, as a children's game, can foster a spirit of solidarity and social harmony which is relevant and should be to be taught to the current generation of children to create harmony in an increasingly diverse society. Therefore, it inspires a sense of urgency to revitalize various folk games that come from tribes from all regions in Indonesia especially in Central Sulawesi, which can have a long-term positive impact on conflict-affected children. A transformation model requires support from families, schools, and communities to achieve the best results. At a basic education level, special learning modules or studies are needed on the importance of social and community values, which can be introduced by competent institutions at the national level.
- Published
- 2022
- Full Text
- View/download PDF
7. High-intensity end-of-life care among Medicare beneficiaries with bladder cancer.
- Author
-
Hugar LA, Yabes JG, Filippou P, Wulff-Burchfield EM, Lopa SH, Gore J, Davies BJ, and Jacobs BL
- Subjects
- Aged, Female, Humans, Male, Medicare, Survival Analysis, Terminal Care methods, United States, Urinary Bladder Neoplasms mortality, Palliative Care methods, Urinary Bladder Neoplasms therapy
- Abstract
Objectives: To quantify the proportion of patients receiving high-intensity end-of-life care, identify associated risk factors, and assess how receipt of palliative care impact end-of-life care; as the delivery of such care, and how it relates to palliative care, has not been reported in bladder cancer SUBJECTS AND METHODS: We conducted a retrospective cohort study of patients with bladder cancer who died within 1 year of diagnosis using Surveillance, Epidemiology, and End Results linked Medicare data. The primary outcome was a composite measure of high-intensity end-of-life care (>1 hospital admission, >1 ED visit, or ≥1 ICU admission within the last month of life; receipt of chemotherapy within the last 2 weeks of life; or acute care in-hospital death). Secondary outcomes included the use of such care over time and any association with the use of palliative care. A generalized linear mixed model assessed for independent determinants., Results: Overall, 45% of patients received high-intensity end-of-life care. This proportion decreased over time. Patients receiving high-intensity care had higher rates of comorbidities, advanced bladder cancer, and nonbladder cancer cause of death. These patients more often received palliative care but, compared to those not receiving high-intensity care, this occurred farther removed from bladder cancer diagnosis and closer to death., Conclusions: Nearly half of Medicare beneficiaries with bladder cancer who die within 1 year of diagnosis receive high-intensity care at the end of life. Palliative care was seldom used and only very near the time of death., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
8. Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer.
- Author
-
Macleod LC, Fam MM, Yabes JG, Hale NE, Turner RM 2nd, Lopa SH, Gingrich JR, Borza T, Skolarus TA, Davies BJ, and Jacobs BL
- Subjects
- Aged, Female, Follow-Up Studies, Humans, Insurance Claim Review, Male, Medicare, Muscle Neoplasms pathology, Neoplasm Invasiveness, Prognosis, Retrospective Studies, SEER Program, Survival Rate, United States, Urinary Bladder Neoplasms pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemotherapy, Adjuvant mortality, Muscle Neoplasms drug therapy, Neoadjuvant Therapy mortality, Urinary Bladder Neoplasms drug therapy
- Abstract
Background: We use observational methods to compare impact of perioperative chemotherapy timing (ie, neoadjuvant and adjuvant) on overall survival (OS) in muscle-invasive bladder cancer because there is no head-to-head randomized trial, and patient factors may influence decision-making., Patients and Methods: Using Surveillance, Epidemiology, and End Results-Medicare data, we identified patients receiving cystectomy for muscle-invasive bladder cancer diagnosed between 2004 and 2013. Patients were classified as receiving neoadjuvant or adjuvant chemotherapy. Propensity of receiving neoadjuvant chemotherapy was determined using gradient boosted models. Inverse probability of treatment weighted survival curves were adjusted for 13 demographic, socioeconomic, temporal, and oncologic covariates., Results: We identified 1342 patients who received neoadjuvant (n = 676) or adjuvant chemotherapy (n = 666) with a median follow-up of 23 months (interquartile range, 9-55 months). Inverse probability of treatment weighted adjustment allows comparison of the groups head-to-head as well as counterfactual scenarios (eg, effect if those getting one treatment were to receive the other). The average treatment effect (ie, "head-to-head" comparison) of adjuvant compared with neoadjuvant on OS was not significant (hazard ratio, 1.14; 95% confidence interval, 0.99-1.31). However, the average treatment effect of the treated (ie, the effect if the neoadjuvant patients were to receive adjuvant instead) was associated with a 33% increase in risk of mortality if they were given adjuvant therapy instead (hazard ratio, 1.33; 95% confidence interval, 1.12-1.57)., Conclusion: Significant treatment selection bias was noted in peri-cystectomy timing, which limits the ability to discriminate differential efficacy of these 2 approaches with observational data. However, patients with higher propensity to receive neoadjuvant therapy were predicted to have increased OS with approach, in keeping with existing paradigms from trial data., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
9. The Development and Validation of Prostate Cancer-specific Physician-Hospital Networks.
- Author
-
Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, Bekelman JE, Nelson JB, Bynum JPW, Barnato AE, and Kahn JM
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, Health Services Needs and Demand, Hospitals, High-Volume statistics & numerical data, Hospitals, Teaching statistics & numerical data, Humans, Male, Physicians statistics & numerical data, Practice Patterns, Physicians' statistics & numerical data, Prostatectomy statistics & numerical data, Prostatic Neoplasms diagnosis, Prostatic Neoplasms epidemiology, Proton Therapy statistics & numerical data, SEER Program statistics & numerical data, United States epidemiology, Watchful Waiting organization & administration, Watchful Waiting statistics & numerical data, Hospitals, Teaching organization & administration, Physicians organization & administration, Practice Patterns, Physicians' organization & administration, Prostatic Neoplasms therapy, Safety-net Providers organization & administration
- Abstract
Objective: To develop prostate cancer-specific physician-hospital networks to define hospital-based units that more accurately group hospitals, providers, and the patients they serve., Methods: Using Surveillance, Epidemiology, and End Results-Medicare, we identified men diagnosed with localized prostate cancer between 2007 and 2011. We created physician-hospital networks by assigning each patient to a physician and each physician to a hospital based on treatment patterns. We assessed content validity by examining characteristics of hospitals anchoring the physician-hospital networks and of the patients associated with these hospitals., Results: We identified 42,963 patients associated with 344 physician-hospital networks. Networks anchored by a teaching hospital (compared to a nonteaching hospital) had higher median numbers of prostate cancer patients (117 [interquartile range {71-189} vs 82 {50-126}]) and treating physicians (7 [4-11] vs 4 [3-6]) (both P <0.001). On average, patients traveled farther to networks anchored by a teaching hospital (49 miles [standard deviation] [207] vs 41 [183]; P <.001). Hospitals known as high-volume centers for robotic prostatectomies, proton-beam therapy, and active surveillance had network rates for these procedures well above the mean. Hospitals known as safety net providers served higher proportions of minorities., Conclusion: We empirically developed prostate-cancer specific physician-hospital networks that exhibit content validity and are relevant from a clinical and policy perspective. They have the potential to become targets for policy interventions focused on improving the delivery of prostate cancer care., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
10. Patterns of stereotactic body radiation therapy: The influence of lung cancer treatment on prostate cancer treatment.
- Author
-
Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, Bekelman JE, Nelson JB, Bynum JPW, Barnato AE, and Kahn JM
- Subjects
- Humans, Lung Neoplasms therapy, Male, Lung Neoplasms secondary, Prostatic Neoplasms complications, Radiosurgery methods
- Abstract
Introduction: Technology availability and prior experience with novel cancer treatments may partially drive their use. We sought to examine this issue in the context of stereotactic body radiation therapy (SBRT) by studying how its use for an established indication (lung cancer) impacts its use for an emerging indication (prostate cancer)., Methods: Using SEER-Medicare from 2007 to 2011, we developed prostate cancer-specific physician-hospital networks. Our primary dependent variable was SBRT use for prostate cancer and our primary independent variable was SBRT use for lung cancer, both at the network level. To assess the influence of SBRT availability and experiential use, we generated predicted probabilities of SBRT use for prostate cancer stratified by a network's use of lung cancer SBRT, adjusting for network characteristics. To assess intensity of use, we examined the correlation between the proportion of prostate cancer patients and lung cancer patients receiving SBRT within a network., Results: We identified 316 networks that served 41,034 prostate cancer and 83,433 lung cancer patients. A network was significantly more likely to use SBRT for prostate cancer if that network used SBRT for lung cancer (e.g., in 2011, odds ratio [OR] 12.7; 95% confidence interval [CI] 3.9-41.8). The Pearson's correlation between the proportion of prostate cancer patients and lung cancer patients receiving SBRT in a network was 0.34, which was not statistically significant (P = 0.12)., Conclusions: SBRT availability and experiential use for lung cancer influences its use for prostate cancer, but intensity of use for one does not relate to intensity of use for the other., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
11. The Influence of Stereotactic Body Radiation Therapy Adoption on Prostate Cancer Treatment Patterns.
- Author
-
Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, Bekelman JE, Nelson JB, Bynum JPW, Barnato AE, and Kahn JM
- Subjects
- Aged, Humans, Longitudinal Studies, Male, SEER Program, United States, Practice Patterns, Physicians' statistics & numerical data, Prostatic Neoplasms radiotherapy, Radiosurgery
- Abstract
Purpose: To our knowledge it is unknown whether stereotactic body radiation therapy of prostate cancer is a substitute for other radiation treatments or surgery, or for expanding the pool of patients who undergo treatment instead of active surveillance., Materials and Methods: Using SEER (Surveillance, Epidemiology, and End Results)-Medicare we identified men diagnosed with prostate cancer between 2007 and 2011. We developed physician-hospital networks by identifying the treating physician of each patient based on the primary treatment received and subsequently assigning each physician to a hospital. We examined the relative distribution of prostate cancer treatments stratified by whether stereotactic body radiation therapy was performed in a network by fitting logistic regression models with robust SEs to account for patient clustering in networks., Results: We identified 344 physician-hospital networks, including 30 (8.7%) and 314 (91.3%) in which stereotactic body radiation therapy was and was not performed, respectively. Networks in which that therapy was and was not done did not differ with time in the performance of robotic and radical prostatectomy, and active surveillance (all p >0.05). The relationship with intensity modulated radiation therapy did not show any consistent temporal pattern. In networks in which it was performed less intensity modulated radiation therapy was initially done but there were similar rates in later years. Brachytherapy trends differed among networks in which stereotactic body radiation therapy was vs was not performed with a lower brachytherapy rate in networks in which stereotactic body radiation therapy was done (p=0.03)., Conclusions: Surgery and active surveillance rates did not differ in networks in which stereotactic body radiation therapy was vs was not performed but when that therapy was done there was a lower brachytherapy rate. Stereotactic body radiation therapy may represent more of an alternative to brachytherapy than to active surveillance.
- Published
- 2020
- Full Text
- View/download PDF
12. Change in Functional Status After Prostate Cancer Treatment Among Medicare Advantage Beneficiaries.
- Author
-
Jacobs BL, Lopa SH, Yabes JG, Nelson JB, Barnato AE, and Degenholtz HB
- Subjects
- Activities of Daily Living, Aged, Humans, Male, Medicare, Retrospective Studies, Self Report, Treatment Outcome, United States, Prostatic Neoplasms therapy
- Abstract
Objective: To examine the relationship between treatment and subsequent functional status among prostate cancer patients., Methods: Using Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey data, we identified men 65 years or older diagnosed with prostate cancer between 1998 and 2009 (follow-up through 2010) who were treated with conservative management, surgery, or radiation. Our primary outcome was functional status as measured by activities of daily living. Secondary outcomes included physical component summary and mental component summary scores, which are both calculated from the Short Form 36 (SF-36) and the Veterans RAND 12-item health survey (VR-12) questionnaires. We included patients who completed 2 surveys and performed propensity score analyses to match patients 1:5 with noncancer controls. We used generalized linear mixed effects models, accounting for clustering due to insurance plan., Results: We identified 408 patients of whom 143 (35%) underwent conservative management, 59 (14%) underwent surgery, and 206 (51%) underwent radiation. Among conservative management and radiation patients, changes in functional status mirrored that of their noncancer controls (all P > .05). Among surgery patients, changes in activities of daily living scores were not significant, but physical component summary (mean difference = 4.5, P < .001) and mental component summary (mean difference = 3.3, P = .01) scores declined slightly more than for their noncancer peers., Conclusion: Surgery patients had a slight decline in their general functional status whereas conservative management and radiation patients had no differences in functional status compared with their noncancer peers. Although the functional status of surgery patients declined more than that of their noncancer peers, this difference may not be clinically significant., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
13. Increasing Utilization of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.
- Author
-
Fam MM, Yabes JG, Macleod LC, Bandari J, Turner RM 2nd, Lopa SH, Furlan A, Filson CP, Davies BJ, and Jacobs BL
- Subjects
- Aged, Aged, 80 and over, Humans, Male, Medicare, United States, Multiparametric Magnetic Resonance Imaging statistics & numerical data, Procedures and Techniques Utilization statistics & numerical data, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms therapy, Watchful Waiting
- Abstract
Objective: To characterize the use of multiparametric magnetic resonance imaging (mpMRI) in male Medicare beneficiaries electing active surveillance for prostate cancer. mpMRI has emerged as a tool that may improve risk-stratification and decrease repeated biopsies in men electing active surveillance. However, the extent to which mpMRI has been implemented in active surveillance has not been established., Methods: Using Surveillance, Epidemiology, and End Results registry data linked to Medicare claims data, we identified men with localized prostate cancer diagnosed between 2008 and 2013 and managed with active surveillance. We classified men into 2 treatment groups: active surveillance without mpMRI and active surveillance with mpMRI. We then fit a multivariable logistic regression models to examine changing mpMRI utilization over time, and factors associated with the receipt of mpMRI., Results: We identified 9467 men on active surveillance. Of these, 8178 (86%) did not receive mpMRI and 1289 (14%) received mpMRI. The likelihood of receiving mpMRI over the entire study period increased by 3.7% (P = .004). On multivariable logistic regression, patients who were younger, white, had lower comorbidity burden, lived in the northeast and west, had higher incomes and lived in more urban areas had greater odds of receiving mpMRI (all P < .05)., Conclusion: From 2008 to 2013, use of mpMRI in active surveillance increased gradually but significantly. Receipt of mpMRI among men on surveillance for prostate cancer varied significantly across demographic, geographic, and socioeconomic strata. Going forward, studies should investigate causes for this variation and define ideal strategies for equitable, cost-effective dissemination of mpMRI technology., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
14. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.
- Author
-
Macleod LC, Yabes JG, Yu M, Fam MM, Hale NE, Turner RM 2nd, Lopa SH, Gingrich JR, Borza T, Skolarus TA, Davies BJ, and Jacobs BL
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols standards, Chemotherapy, Adjuvant standards, Chemotherapy, Adjuvant trends, Cisplatin therapeutic use, Cystectomy statistics & numerical data, Female, Humans, Male, Marital Status statistics & numerical data, Medicare statistics & numerical data, Neoadjuvant Therapy standards, Neoplasm Invasiveness, Neoplasm Staging, Perioperative Care standards, Practice Guidelines as Topic, Practice Patterns, Physicians' statistics & numerical data, Retrospective Studies, SEER Program statistics & numerical data, Sex Factors, United States, Urinary Bladder Neoplasms pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoadjuvant Therapy trends, Perioperative Care trends, Practice Patterns, Physicians' trends, Urinary Bladder Neoplasms therapy
- Abstract
Introduction: Contemporary guidelines recommend cystectomy with neoadjuvant or adjuvant cisplatin-based chemotherapy given with curative intent for patients with resectable muscle-invasive bladder cancer (MIBC). However, rates and appropriateness of perioperative chemotherapy utilization remain unclear. We therefore sought to characterize use of perioperative chemotherapy in older radical cystectomy MIBC patients and examine factors associated with use., Methods: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we identified patients with MIBC diagnosed between 2004 and 2013 and treated with radical cystectomy. We classified patients into 3 treatment groups: cystectomy alone, neoadjuvant, or adjuvant chemotherapy. Chemotherapy was classified by regimen. We then fit a multinomial multivariable logistic regression model to assess association between patient factors with the receipt of each treatment., Results: We identified 3,826 eligible patients. The majority (484; 65%) received cystectomy alone. Neoadjuvant (676; 18% overall, 69% cisplatin-based), and adjuvant chemotherapy (666, 17% overall, 55% cisplatin-based) were used in similar proportions of cystectomy patients. Over the study period, the odds of receiving adjuvant chemotherapy decreased by 7.5%, whereas neoadjuvant therapy increased by 27.5% (both P < 0.001). There was an increase in use of cisplatin-based regimens in the neoadjuvant setting (35 to 72%, P < 0.001), but not the adjuvant setting. Female gender, lower comorbidity, married status, and lower stage disease were associated with greater odds of receiving neoadjuvant chemotherapy (all P < 0.05)., Conclusion: From 2004 to 2013 use of neoadjuvant chemotherapy for MIBC increased while use of adjuvant chemotherapy decreased. Future studies examining barriers to appropriate chemotherapy use, and the comparative effectiveness of neoadjuvant versus adjuvant chemotherapy are warranted., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
15. Palliative care use amongst patients with bladder cancer.
- Author
-
Hugar LA, Lopa SH, Yabes JG, Yu JA, Turner RM 2nd, Fam MM, MacLeod LC, Davies BJ, Smith AB, and Jacobs BL
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, Facilities and Services Utilization, Female, Humans, Male, SEER Program, Socioeconomic Factors, Time-to-Treatment, United States, Urinary Bladder Neoplasms pathology, Palliative Care statistics & numerical data, Urinary Bladder Neoplasms therapy
- Abstract
Objectives: To describe the rate and determinants of palliative care use amongst Medicare beneficiaries with bladder cancer and encourage a national dialogue on improving coordinated urological, oncological, and palliative care in patients with genitourinary malignancies., Patients and Methods: Using Surveillance, Epidemiology, and End Results-Medicare data, we identified patients diagnosed with muscle-invasive bladder cancer (MIBC) between 2008 and 2013. Our primary outcome was receipt of palliative care, defined as the presence of a claim submitted by a Hospice and Palliative Medicine subspecialist. We examined determinants of palliative care use using logistic regression analysis., Results: Over the study period, 7303 patients were diagnosed with MIBC and 262 (3.6%) received palliative care. Of 2185 patients with advanced bladder cancer, defined as either T4, N
+ , or M+ disease, 90 (4.1%) received palliative care. Most patients that received palliative care (>80%, >210/262) did so within 24 months of diagnosis. On multivariable analysis, patients receiving palliative care were more likely to be younger, female, have greater comorbidity, live in the central USA, and have undergone radical cystectomy as opposed to a bladder-sparing approach. The adjusted probability of receiving palliative care did not significantly change over time., Conclusions: Palliative care provides a host of benefits for patients with cancer, including improved spirituality, decrease in disease-specific symptoms, and better functional status. However, despite strong evidence for incorporating palliative care into standard oncological care, use in patients with bladder cancer is low at 4%. This study provides a conservative baseline estimate of current palliative care use and should serve as a foundation to further investigate physician-, patient-, and system-level barriers to this care., (© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.)- Published
- 2019
- Full Text
- View/download PDF
16. The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.
- Author
-
Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, Schroeck FR, Bekelman JE, Kahn JM, Nelson JB, and Barnato AE
- Subjects
- Age Factors, Aged, Aged, 80 and over, Humans, Logistic Models, Male, Medicare, Multivariate Analysis, Neoplasm Grading, Prostatic Neoplasms pathology, SEER Program, United States, Prostatic Neoplasms therapy, Radiosurgery statistics & numerical data, Radiotherapy, Intensity-Modulated statistics & numerical data
- Abstract
Background: Several new prostate cancer treatments have emerged since 2000, including 2 radiotherapies with similar efficacy at the time of their introduction: intensity-modulated radiotherapy (IMRT) and stereotactic body radiation therapy (SBRT). The objectives of this study were to compare their early adoption patterns and identify factors associated with their use., Methods: By using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, patients who received radiation therapy during the 5 years after IMRT introduction (2001-2005) and the 5 years after SBRT introduction (2007-2011) were identified. The outcome of interest was the receipt of new radiation therapy (ie, IMRT or SBRT) compared with the existing standard radiation therapies at that time. The authors fit a series of multivariable, hierarchical logistic regression models accounting for patients nested within health service areas to examine the factors associated with the receipt of new radiation therapy., Results: During 2001 to 2005, 5680 men (21%) received IMRT compared with standard radiation (n = 21,555). Men who received IMRT were older, had higher grade tumors, and lived in more populated areas (P < .05). During 2007 through 2011, 595 men (2%) received SBRT compared with standard radiation (n = 28,255). Men who received ng SBRT were more likely to be white, had lower grade tumors, lived in more populated areas, and were more likely to live in the Northeast (P < .05). Adjusting for cohort demographic and clinical factors, the early adoption rate for IMRT was substantially higher than that for SBRT (44% vs 4%; P < .01)., Conclusions: There is a stark contrast in the adoption rates of IMRT and SBRT at the time of their introduction. Further investigation of the nonclinical factors associated with this difference is warranted. Cancer 2017;123:2945-54. © 2017 American Cancer Society., (© 2017 American Cancer Society.)
- Published
- 2017
- Full Text
- View/download PDF
17. Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population.
- Author
-
Jacobs BL, Lopa SH, Yabes JG, Nelson JB, Barnato AE, and Degenholtz HB
- Subjects
- Aged, Follow-Up Studies, Humans, Male, Neoplasm Grading, Neoplasm Staging, Prognosis, Prostatic Neoplasms epidemiology, Prostatic Neoplasms psychology, SEER Program, United States epidemiology, Watchful Waiting, Activities of Daily Living, Choice Behavior, Medicare Part C statistics & numerical data, Patient Preference, Prostatic Neoplasms therapy
- Abstract
Background: There are several effective treatments for prostate cancer. To what extent a patient's functional status influences the treatment decision is unknown. This study examined the association between functional status and treatment among older men with prostate cancer., Methods: Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey data were used to identify men who were 65 years old or older and were diagnosed with prostate cancer between 1998 and 2009. The primary outcome was treatment choice: conservative management, surgery, or radiation within 1 year of the diagnosis. The exposure was the functional status assessed as 4 measures within 3 domains: 1) physical function (activities of daily living [ADLs] and physical component summary score), 2) cognitive function (survey completer: self vs proxy), and 3) emotional well-being (mental component summary score). A multivariate, multinomial logistic regression was fitted with adjustments for several patient, tumor, and regional characteristics., Results: This study identified 508 conservative management patients, 195 surgery patients, and 603 radiation patients. Compared with men with no ADL dependency, those with any ADL dependency had lower odds of receiving surgery (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.38-0.99) or radiation (OR, 0.58; 95% CI, 0.43-0.78) versus conservative management. ADL dependency did not differ when surgery and radiation were compared. Patients with a proxy survey response were less likely to receive surgery or radiation versus conservative management., Conclusions: Functional status is associated with treatment choice for men with prostate cancer. Future research should examine whether this is due to physician recommendations, patient preferences, or a combination. Cancer 2016;122:3199-206. © 2016 American Cancer Society., (© 2016 American Cancer Society.)
- Published
- 2016
- Full Text
- View/download PDF
18. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.
- Author
-
Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, and Wolmark N
- Subjects
- Adenocarcinoma mortality, Aged, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Agents adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bevacizumab, Colonic Neoplasms mortality, Disease-Free Survival, Female, Fluorouracil administration & dosage, Follow-Up Studies, Humans, Leucovorin administration & dosage, Male, Middle Aged, Neoplasm Staging, Organoplatinum Compounds administration & dosage, Adenocarcinoma drug therapy, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Agents administration & dosage, Colonic Neoplasms drug therapy
- Abstract
Purpose: The National Surgical Adjuvant Breast and Bowel Project trial C-08 was designed to investigate the safety and efficacy of adding bevacizumab to fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) for the adjuvant treatment of patients with stage 2-3 colon cancer. Our report summarizes the primary and secondary end points of disease-free and overall survival, respectively, with 5 years median follow-up time., Patients and Methods: Patients received modified FOLFOX6 once every 2 weeks for a 6-month period (control group) or modified FOLFOX6 for 6 months plus bevacizumab (5 mg/kg) once every 2 weeks for a 12-month period (experimental group). The primary end point of the study was disease-free survival (DFS) and overall survival (OS) was a secondary end point., Results: Of 2,673 analyzed patients, demographic factors were well-balanced by treatment. With a median follow-up of 5 years, the addition of bevacizumab to mFOLFOX6 did not result in an overall significant increase in DFS (hazard ratio [HR], 0.93; 95% CI, 0.81 to 1.08; P = .35). Exploratory analyses found that the effect of bevacizumab on DFS was different before and after a 1.25-year landmark (time-by-treatment interaction P value <.0001). The secondary end point of OS was no different between the two study arms for all patients (HR, 0.95; 95% CI, 0.79 to 1.13; P = .56) and for those with stage 3 disease (HR, 1.0; 95% CI, 0.83 to 1.21; P = .99)., Conclusion: Bevacizumab for 1 year with modified FOLFOX6 does not significantly prolong DFS or OS in stage 2-3 colon cancer. We observed no evidence of a detrimental effect of exposure to bevacizumab. A transient effect on disease-free survival was observed during bevacizumab exposure in the study's experimental arm.
- Published
- 2013
- Full Text
- View/download PDF
19. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.
- Author
-
McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, Giguere JK, Dakhil SR, Fehrenbacher L, Lopa SH, Wagman LD, O'Connell MJ, and Wolmark N
- Subjects
- Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bevacizumab, Colonic Neoplasms mortality, Colonic Neoplasms pathology, Female, Fluorouracil adverse effects, Fluorouracil therapeutic use, Gastrointestinal Hemorrhage epidemiology, Humans, Intestinal Obstruction epidemiology, Intestinal Perforation epidemiology, Leucovorin adverse effects, Leucovorin therapeutic use, Male, Middle Aged, Organoplatinum Compounds adverse effects, Organoplatinum Compounds therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colonic Neoplasms drug therapy, Neoplasm Metastasis drug therapy
- Abstract
Purpose: Major concerns surround combining chemotherapy with bevacizumab in patients with colon cancer presenting with an asymptomatic intact primary tumor (IPT) and synchronous yet unresectable metastatic disease. Surgical resection of asymptomatic IPT is controversial., Patients and Methods: Eligibility for this prospective, multicenter phase II trial included Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1, asymptomatic IPT, and unresectable metastases. All received infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) combined with bevacizumab. The primary end point was major morbidity events, defined as surgical resection because of symptoms at or death related to the IPT. A 25% major morbidity rate was considered acceptable. Secondary end points included overall survival (OS) and minor morbidity related to IPT requiring hospitalization, transfusion, or nonsurgical intervention., Results: Ninety patients registered between March 2006 and June 2009: 86 were eligible with follow-up, median age was 58 years, and 52% were female. Median follow-up was 20.7 months. There were 12 patients (14%) with major morbidity related to IPT: 10 required surgery (eight, obstruction; one, perforation; and one, abdominal pain), and two patients died. The 24-month cumulative incidence of major morbidity was 16.3% (95% CI, 7.6% to 25.1%). Eleven IPTs were resected without a morbidity event: eight for attempted cure and three for other reasons. Two patients had minor morbidity events only: one hospitalization and one nonsurgical intervention. Median OS was 19.9 months (95% CI, 15.0 to 27.2 months)., Conclusion: This trial met its primary end point. Combining mFOLFOX6 with bevacizumab did not result in an unacceptable rate of obstruction, perforation, bleeding, or death related to IPT. Survival was not compromised. These patients can be spared initial noncurative resection of their asymptomatic IPT.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.